Table 5.

Comparisons of health care utilization and health care expenditures by type of payer, 2008.

	Medicaid	Employer-sponsored insurance (ESI) [6]	P-value
Health care utilization
No. of people	1164	435	–
No. of people w an inhibitor (% of haemophilia A)	27 (7%)	30 (3%)	<0.01‡
No. of people with admission (%)	95 (22%)	164 (14%)	<0.01‡
No. of admission w ≥1 admission(s)	2.2 (2.2)	1.4 (1.0)	<0.01†
No. of people with ED visit (%)	224 (51%)	379 (33%)	<0.01‡
No. of ED visits w ≥1 visit (s)	3.3 (4.5)	2.8 (6.4)	0.29†
Health care expenditures (mean[median])			Ratio (Medicaid/ESI)¶ [6]
All	142 987 [46 737]	155 136 [73 548]	0.9† [0.6§**]
Children	113 867 [31 067]	150 680 [72 374]	0.8† [0.4§**]
Haemophilia A
w/o an inhibitor	83 981 [23 697]	142 057 [73 659]	0.6†**[0.3§**]
w an inhibitor	509 778 [55 038]	831 866 [461 527]	0.6 [0.1§]
Haemophilia B	125 522 [49 521]	92 546 [36 177]	1.4†[1.4§]
Adult	194 549 [73 291]	159 310 [76 088]	1.2†[1.0§]
w/o an inhibitor
w/o blood-borne viral infection	184 765 [62 785]	125 861 [43 968]	1.5†*[1.4§]
w blood-borne viral infection	178 648 [101 446]	188 056 [116 207]	0.9†[0.9§]
w an inhibitor	355 552 [344 607]	577 640 [176 218]	0.6†[2.0§]

^*and

^**represent a 5% and a 1% level of significance, respectively.

^†t-test.

^‡Chi-squared test.

^§Wilcoxon–Mann–Whitney test.

^¶To compare mean and median estimates, we used t-tests and Wilcoxon–Mann–Whitney test, respectively.